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ABSTRACT
The vast numbers of individuals now infected with the
HIV-1 virus and its spread to all corners of the globe
have been well chronicled. It is difficult to convey,
however, the desperation and hopelessness of the
majority of those HIV-1-infected individuals that live in
regions where resources are sparse. Pursuit of the
unique and complex medical and societal issues
relating to the HIV pandemic is globally creating a
discrete area within the field of infectious disease. The
consequences of the severe immunologic compromise
resulting from HIV-1 infection vary from those seen in
the West, both in terms of entities and their frequency.
While a number of antiretroviral distribution programs
are in place, the development of guidelines that
simplify antiretroviral regimens, enrollment in treat-
ment programs, and monitoring remain difficult.
Furthermore, the epidemiology, response to antiretro-
viral therapy, and resistance patterns of non-B sybtypes
await further elucidation. The goals that have been set
may be compromised by concomitant endemic diseases
(such as tuberculosis and malaria), unpreventable
mother-to-child transmission, malnutrition, poor sani-
tation, inadequate public health systems, and, espe-
cially, the lack of an adequate healthcare workforce.
However, awareness of these impediments is growing.
The understanding of the complex and diverse
economic, political and cultural forces entwined with
and driving the epidemic is evolving. Finally, the need for
a long-term, multifaceted response to the broad crisis in
underdeveloped nations where AIDS is but one of a
number of critical elements is becoming appreciated. 
GLOBAL HIV-1 MEDICINE IS A DISTINCT ENTITY
We adoringly call them the “Shashemene Kids.” Barely
20 years old and with no medical training whatsoever,
they have assumed responsibility with extraordinary
courage and humility. The town of Shashemene is about
four hours drive south of Addis Abeba, amongst the Rift
Valley Lakes. A crossroads for southern Ethiopia, it
sprawls over a large area. It is crowded and poor, its
myriad unpaved passageways stringing together
meager earthen dwellings interspersed with brightly
colored fruit and vegetable markets. AIDS abounds in
Shashemene, where seroprevelence was estimated at
13% in 2002 (United Nations Children’s Fund/WHO/
UNAIDS, 2004). Advanced AIDS patients are often cast
away here, once their emaciation and debilitation make
the diagnosis impossible to camouflage. 
Appalled by the situation and undaunted by either
their lack of training or any support, the “Sheshamene
Kids” began to provide solace and care. Inside a small
dirt compound, encircled by a few dark rooms
furnished with only the most thin and tattered of
mattresses, they gave a home to the abandoned,
impoverished, and desperately sick. With kindness and
vigilance they attend to their patients’ every need to
the best of their abilities and resources. They rejoice in
what is possible, and are undeterred by what is not. 
We finally found them on a Sunday morning. The three
of us were all clinicians well experienced with the toll
the HIV-1 virus can take on the human body. Our hosts
were excited that we had come and were honored that
we wanted to see their patients. Of their approxi-
mately 20 charges, the ones who could still walk had
gone to church with some of the staff. We saw those
who could not go. One lady was febrile and
diaphoretic, had a massively enlarged and tender
spleen, and could not sit up. Another young woman
was febrile, tachypneic, and coughing incessantly. A
third lady was barely arousable, almost immobile, and
wasted to a mere skeleton. A fourth lady was in agony
with shaking chills and an acute abdomen. There were
others. There was no medical care and no medicine.
Once infected with HIV-1, the inexorable progression to
suffering, debility, humiliation, and early death is the
reality for most individuals in poor countries. Each indi-
vidual death often leaves an additional wake of misery
in the form of infected sexual partners, infected chil-
dren, the inability of the family unit to sustain itself,
and orphans. Since 1999, the average life span for
persons born between 1995-2000 has now decreased by
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13 years to 49 years in seven African countries with HIV
seroprevelences exceeding 20% (Joint United Nations
Programme on HIV/AIDS (UNAIDS), 2004a). In Swazi-
land, Zambia, and Zimbabwe the life expectancy of
those born in the next decade may drop below 35 years
without antiretroviral therapy (ART) (UNAIDS, 2004a). 
The medical and social science of the global AIDS
pandemic is rapidly becoming a distinct arena within
the field of HIV medicine. The opportunistic conse-
quences of HIV-1 infection vary both in terms of enti-
ties and the magnitude of disease burden. The HIV-1
epidemic confounds and is confounded by existing
concomitant epidemics of tuberculosis, malaria, and
other sexually transmitted diseases. HIV is the most
powerful known risk factor for reactivation of latent
tuberculosis infection. Once infected with tuberculosis,
there is an increased risk to develop active tuberculosis
with increased likelihood of disseminated disease.
There is also increased risk of re-infection with tuber-
culosis for those infected with HIV-1. To succeed in
managing tuberculosis, HIV must be addressed; to
address HIV, tuberculosis must be controlled. 
Tuberculosis competes with bacteremias as the most
common of HIV-related infections (Holmes et al., 2003).
Prominent bacteremias include those from non-
typhoidal Salmonella species and Streptococcus pneu-
moniae. Diarrheal diseases are prevalent, caused not
only by bacterial pathogens, but also by the entities of
cryptosporidiosis, microsporidiosis, and isosporiosis
(Holmes et al., 2003). Fulminant neurological disease is
common, especially as a result of toxoplasmosis and
cryptococcal meningitis. For the majority of these infec-
tions, diagnostic tests and many therapeutic modali-
ties, both for treatment and prophylaxis, are either
unavailable or are only sporadically available. Further-
more, it is now accepted that there are significant
interactions between malaria and HIV, especially in
pregnant women (Ter Kuile et al., 2004). Co-infected
FIGURE 1: The Limitations of Healthcare in Africa Include Poverty and the Lack of Resources.  A. The streets of Awasa, a town on
one of the Rift Valley Lakes.  Note that the means of transportation are limited to a few automobiles and horse-drawn buggies. 
B. A tukul (hut) typical of Ethiopian villages. C. The main livelihood of Ethiopians stems from agriculture.  Shown here are three
women who walk 8-10 km down from the surrounding mountainside where they harvest eucalyptus stalks to sell as firewood at
the market.  D. A remote hospital complex in Aiyra of Western Ethiopia.  E. A health post serving the medical care needs of about
5,000 people in Southern Ethiopia. F. The Alert Hospital complex used for isolation of tuberculosis patients in Addas.  Alert serves
a region of about 750,000 residents.  G. Computers and filing systems are scarce in most of Africa.  Therefore, the healthcare statis-
tics in the health post are maintained by hand on paper charts, posted on the wall.  H. Shown here is Dr. Zenebe, an academic
Ethiopian physician from Addis Abebe University and also a participating faculty member for the Albert Einstein College of Medi-
cine Global Institute of HIV Medicine.  He is teaching in a conference on HIV management for regional physicians and nurses.
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pregnant women experience more frequent malaria
(both peripheral and placental), a higher level of 
parasitemia, and more severe anemia. Their infants
also have lower birth weights (Ter Kuile et al, 2004).
Mother-to-child transmission (MTCT) of HIV-1, virtually
eliminated from developed countries, continues almost
unabated in the less privileged regions of the world,
where ART is not available, where the reproductive
health care infrastructure is minimal, and where alter-
natives to breast-feeding are usually not affordable,
sustainable, safe, or culturally acceptable (World
Health Organization (WHO), 2004a). The toll is stag-
gering, especially in sub-Saharan Africa, where more
than 500,000 infants were vertically infected in 2003.
Without intervention, 25 to 45% of HIV-1-infected
women who breastfeed will transmit HIV-1 to their
infants; almost double the 15 to 30% transmission rates
that occur cumulatively through pregnancy and during
the peripartum period (WHO, 2004a). Following publi-
cation of the initial vanguard study of the three-part
prophylactic regimen of AZT in the US (Conner et al.,
1994), further clinical trials and observational studies
have proven the effectiveness of shorter, simpler, and
less expensive MTCT regimens in resource-limited
settings (WHO, 2004a). Further trials are underway or
planned to evaluate infant prophylaxis for varying
periods of time postpartum, or to provide maternal
ART during breastfeeding for women who otherwise
would not meet ART initiation criteria (Newell and
Thorne, 2004). Drug resistance in mothers and infants
induced by regimens to prevent MTCT that do not fully
suppress the virus is a growing concern. The clinical
consequences of viral resistance following short-course
prophylaxis to prevent MTCT and the potential to
compromise future ART are pressing issues under
investigation.
Beyond the prevention of MTCT, the international
community has now launched a massive effort to
expand access to ART globally (WHO, 2003a). It is
committed to find ways to translate the HIV-1-related
care and ART that evolved in the context of the tertiary
care available in the US, Europe, and Australia for
application in areas of the world in which almost no
infrastructure exists. These are areas in which HIV-1
subtype B, found most commonly in the West, does not
predominate. There is much to be clarified and
described in terms of the transmission efficiency, path-
ogenicity, efficacy of antiretroviral drugs, and patterns
of drug resistance for the multiple other HIV-1
subtypes that are prevalent in these areas. The World
Health Organization (WHO) has crafted guidelines for
staging HIV-1 disease and initiating ART in resource-
constrained settings, has recommended first- and
second-line treatment regimens, and has suggested
tiers of laboratory tests for enrollment and monitoring
based on availability (WHO, 2003a).
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THE HIV-1 CRISIS ON AN INDIVIDUAL LEVEL
It is one thing to know that minimal infrastructure
exists; it is an entirely different matter to try to func-
tion in such settings. Consider the following situation
of one young woman being evaluated for a demon-
stration project to provide ART in Addis late in 2004.
Although she did not know her birthday, by her
family’s historical account she was about 36 years old.
Both her husband (who had been in the military) and
she were health assistants and had worked in hospitals.
She had been married to her husband, her only sexual
partner, for about 10 years. He had died five years prior
following a wasting illness that she presumed was
AIDS. She had been unwell since her husband’s death
and was treated for nine months until the spring of
2004 for inguinal TB lymphadenitis. At the completion
of the tuberculosis treatment she had weighed about
110 pounds. During the intervening eight months she
had become much weaker with anorexia, dysphagia,
and fever; she was unable to work and provide food for
her two children aged six and ten. She was admitted to
the hospital in late 2004, delirious, with a temperature
of 104oF, weighing about 90 pounds, and with severe
oral and presumed esophageal candidiasis. The only
laboratory examination was a hemoglobin level of 7.5,
a white blood cell count of 3,250, and a blood smear,
which demonstrated no hemoparasites. On a treatment
regimen of ceftriaxone and gentamycin her tempera-
ture began to abate from 102-104oF to 99-100oF over
the ensuing several days. Her mental status improved
although she was too weak to get out of bed, but she
then experienced two grand mal seizures. With no
ability to measure electrolytes, determine acid/base
status, image her brain, or evaluate her otherwise for
AIDS-related CNS pathology, she was simply monitored.
Although we could not further define co-morbidities
and HIV-1-related co-infections, we planned to start
her on ART. Unfortunately, she died within the next
two weeks, before that could be done. 
AIDS IN THE CONTEXT OF A BROAD CRISIS IN 
UNDERDEVELOPMENT  
The failure of developing countries to better cope with
the AIDS pandemic, especially countries in sub-Saharan
Africa, is symptomatic of a poor economic state and
thus, fundamental inadequacies in their healthcare
delivery systems. Ethiopia, for example, is one of the
poorest countries worldwide, with a per capita annual
income only reaching US $100 (UNAIDS, 2004b). Crip-
pled by limited resources (even where foreign assis-
tance flows freely), the ability of developing nations to
combat AIDS as well as a host of other endemic
diseases, such as tuberculosis and malaria, is compro-
mised by weak infrastructure, concomitant issues such
as malnutrition and poor sanitation, and inadequate
public health systems (see Figure 1).
The WHO-supported Commission on Macroeconomics
and Health estimated that healthcare spending in the
poorest countries of the world is approximately US $57
billion short of the minimum required for the provision
of non-AIDS-related basic care (Commission on Macro-
economics and Health, 2001). Although there are a
number of contributory factors behind the continuing
collapse of healthcare infrastructure, chief among them
is reduced public expenditure on health. For example,
26 of the poorest African countries fall below the 
US $60 per capita figure advocated by WHO-affiliated
health economists (Evans et al., 2001). Yet, despite
continuing civil society advocacy and for myriad
reasons—none of which is acceptable—public health
spending in developing countries, both per capita and
as a percentage of gross domestic product (GDP),
remains considerably lower than in economically sound
G8 nations (United Nations Development Programme,
2004). 
Health systems in the developing world would still be
overburdened even without AIDS. For example, other
infectious and parasitic diseases killed roughly 3.5
million people in Africa in 2002 (WHO, 2004b)—more
than half as many as died from AIDS that same year
(WHO, 2004b; UNAIDS/WHO, 2002). Tragically, AIDS is
very much present, and it is in full assault against devel-
oping countries, straining their already strained health
systems. So much so that despite an influx of resources
directed against HIV/AIDS (as well as other endemic
diseases of poverty), the absence of an effective public
healthcare system in poorer countries undermines
interventions supported by donors such as the Global
Fund Against AIDS, Tuberculosis & Malaria (Global
Fund). Indeed, the Global Fund’s initial assessment of
the situation in AIDS-ravaged Africa predicted that
“the greatest burden of [AIDS, tuberculosis, and
malaria] falls on Africa… [where] AIDS, and [tubercu-
losis] linked to AIDS, and malaria, are straining an
already frayed public health infrastructure (United
Nations Children Fund/ UNAIDS/WHO, 2000).”
Personnel Shortages 
Perhaps the most serious reflection of the collapse of
health systems—and one of the greatest threats to
expanded access to antiretroviral therapy—lies in the
situation regarding health personnel. While data lag
far behind their need for quantitative and qualitative
purposes and, indeed, prove difficult to compile, a
number of institutions have, through various mecha-
nisms, identified significant weaknesses in human
resource availability and capacity. Among these are
shortages of personnel to deliver care, insufficient
training to allow for the delivery of optimal care, lack
of support to facilitate its delivery, and the absence of
incentives through which health personnel may remain
on the front-lines of care delivery (Narasimhan et al.,
2004; World Bank, 2003). Some health systems analysts
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have suggested that current efforts to scale-up access
to ART may fail as a direct result of these weaknesses
(Kober and Damme, 2004).
With regard to personnel shortages, physician to
patient ratios in most developing countries fall well
short of expectations—and have done so as a matter of
historical perspective. According to a US Agency for
International Development (USAID) study, in countries
such as Ethiopia and Tanzania, the physician to patient
ratio stands at 1:≥30,000; the situation is not much
improved in countries such as Côte d’Ivoire and Senegal
(1:10,000); and, while certainly more reassuring, the
physician to patient ratio in more affluent countries
such as Botswana and South Africa (1:5,000) remains an
obstacle to the provision of quality care (USAID, 2003).
The human resources crisis similarly affects other
health professionals—including nurses, most of whom
bear the brunt of care in the developing world. Nurse
to patient ratios range from 1:≥10,000 in Mali, to
1:5,000 in Uganda (USAID, 2003). While no one argues
that this ratio should mirror that of developed coun-
tries (average = 1:300 physician to patient; 1:1,000
nurse to patient [USAID, 2003]), there must be a
concerted effort to address this burgeoning crisis.
Insufficient Training
Insufficient appropriate and/or adequate training—
without which any hopes for the safe and optimal
delivery of antiretroviral therapy may be dashed—
exacerbates the burden created by personnel short-
ages. An American Foundation for AIDS Research
(amfAR) study revealed, for example, how a severe
shortage of trained physicians in Asia may be slowing
progress in scale-up efforts. According to the study,
among six high-burden Asian countries, the HIV-
trained physician to HIV-positive patient ratio varies
from a high of 1:3,140 in Cambodia to a low of 1:11,250
in Vietnam (amFAR, 2004). 
Yet, even among those physicians considered “trained”
via various educational interventions, there exist such
overwhelming knowledge gaps that the need for an
increased focus on human capacity-building is crystal
clear. Field-testing by the International Association of
Physicians in AIDS Care (IAPAC) of a proctored certifi-
cation examination among a group of developing
world physicians identified major gaps in knowledge
deemed necessary for the management of antiretro-
viral therapy in resource-limited settings. Among 250
African physicians taking the examination, whose
passing score is 70 percent or higher, the average scores
across four critical areas of ART delivery were: 46.85%
(delivery of adult/adolescent antiretroviral therapy),
40.80% (pediatric antiretroviral therapy), 61.02%
(prevention of mother-to-child transmission), and
38.46% (occupational post-exposure prophylaxis)
(IAPAC, 2004a). These gaps, if not addressed, jeop-
ardize not just the short-term goal of placing more
patients on ART, (WHO, 2003b) but the longer-term aim
of keeping patients on ART, achieving viral suppres-
sion, and mitigating the onset of antiretroviral drug
resistance.
Lack of Clinical/Technical Support
In those countries in which antiretroviral therapy
programs have been launched—in however limited a
manner—there also exists a general misconception that
one-time (or silo) training activities of varying intensity
represent sufficient capacity-building interventions.
Given the lack of formal HIV/AIDS-specific pre-service
training provided in most developing world medical
schools, and the relative ad hoc nature of vertical
training activities coordinated by disparate (albeit like-
minded) academic institutions, as well as non-govern-
mental and non-academically-affiliated entities, there
is a pressing need for ongoing clinical support of physi-
cians and allied healthcare professionals via various
means. These include, for example, technology-facili-
tated warmlines and continuing education (CE) activi-
ties, as well as technical assistance around program
implementation. However such support is neither in
abundance nor is it consistently implemented. For
example, only a handful of more affluent developing
countries are experimenting with technology-based
mentoring; and too few have regulated CE activities as
a means to guarantee continuous educational/practical
reinforcement for health-care personnel (IAPAC,
2004b). As for technical assistance targeted at
successful program implementation, this remained in
scarce supply until very recently, when numerous insti-
tutions such as the WHO, Clinton HIV/AIDS Initiative,
and USAID ramped up their respective efforts in this
area (Institute of Medicine, 2004). 
Lack of Resources
Sadly, even where health personnel are trained and
offered support, there remains a lack of incentive to
secure their involvement in the clinical management of
HIV/AIDS either beyond a few years or within their
countries. In addition to the stigma that continues to
be associated with HIV disease—among patients, fami-
lies, care providers, and communities—there is the
reality that AIDS does not exist in a vacuum. Co-existing
with endemic diseases such as tuberculosis and malaria,
and illnesses caused by malnutrition and poor sanita-
tion, HIV disease places strains not just on health
systems, but also on health professionals. 
A recent study in support of the U.S. President’s Emer-
gency Plan for AIDS Relief (PEPFAR) illustrated the
burden by reflecting on per-patient time requirements
in minutes across a cadre of health personnel
managing a patient on ART, assuming no delegation of
duties to community health workers. Assuming scale-
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up of access to ART for 10,000 patients in Zambia, the
study calculated 90 minutes per year of a physician’s
time required per patient just for the management of
ART; not to mention an additional 105 minutes per
episode per patient to manage complications such as
oral candidiasis and meningitis, as well as co-infectious
diseases such as tuberculosis (Smith et al., 2004). Under
this scenario—understanding that time requirements
will vary based on whether a patient is being initiated
versus maintained on ART the researchers estimated a
need for 206 physicians by 2006 dedicated to deliver
such care; a figure that represents close to one-third of
Zambia’s existing physician workforce (Smith et al.,
2004). When one-third of a country’s physicians are
required to deliver quality ART-based care, the chal-
lenge of delivering other priority and non-priority
health services becomes glaringly evident. 
Another challenge lies in the fact that a significant
percentage of physicians and allied health profes-
sionals from the developing world are lured to more
developed or outright developed countries by the
incentive of higher wages, improved living conditions,
and increased opportunity for career advancement
(Padarath et al., 2003). Additionally contributing signif-
icantly to this “brain drain” is the frustration and disil-
lusionment experienced when professionals are unable
to apply medical knowledge to improve individual lives
due to lack of diagnostic and therapeutic modalities
and support staff. Another recent study of the health
personnel workforce in Zambia found that the average
loss of HIV/AIDS service delivery staff was 30% annu-
ally, predictably complicating the expansion of ART
program (Huddart et al., 2004). “Brain drain”, however,
occurs not only as professionals leave their countries,
but also as they distribute themselves within countries.
They gravitate to the private sector from the public
sector where income is more lucrative, resources are
more available, and there is greater autonomy; they
gravitate to the urban from the rural settings.
Certainly, the crisis around health personnel is but one
in a mix of other interrelated factors such as crumbling
(or non-existent) physical infrastructure and inefficient
(or unreliable) drug supply chains. Nonetheless, this
crisis poses perhaps the greatest risk because without
the health professions to educate, administer care, and
monitor its progress, the miracle of modern medicine
espoused by ART (and taken for granted in developed
countries where such health personnel crises are rare)
could escape countless men, women, and children
living with HIV/AIDS in the developing world.
LOOKING TOWARDS THE FUTURE
When mythical Pandora opened the forbidden box, it
spewed forth a horde of miseries into the world. The
only good that it contained, intact at the bottom of the
box, was hope. To this day it remains man’s comfort
and salvation. An internationally galvanized response
to the world’s crisis in underdevelopment, especially in
Africa, with a pragmatic and strategic long-term
response to the AIDS pandemic as its centerpiece, is a
hope that can be realized. This hope has recently been
inspiringly portrayed in two documents. 
The National Academy of Sciences insightfully summa-
rizes the current situation, and especially highlights the
dearth of healthcare workers that existed in much of
the less-developed world even before the current
pandemic occurred (National Academy of Sciences,
2005). It boldly proposes the creation of a U.S. Global
Health Service as a new national program to provide US
expertise to help host countries establish and sustain
their health workforce and capacity. The proposal
provides plans for six linked areas under a single
management structure including designs for (1) a
global health service core, (2) a health workforce needs
assessment capability, (3) a fellowship program, (4) a
loan repayment program, (5) a twinning program and
(6) a clearing house for information collation and
exchange. Finally, it considers ways to sustain devel-
oping health forces by addressing the needs for long-
term health force capacity development, creative
partnerships, electronic technology and global health
education within the U.S.
The second document is a richly textured book
published by UNAIDS and entitled “AIDS in Africa-
Three Scenarios to 2025” (UNAIDS, 2005). It projects
into the next two decades and analyzes three different
pathways the global community can adopt to confront
the AIDS epidemic. The first scenario entitled “Traps
and Legacies: The Whirlpool” extends the current
trends for the next twenty years. It illustrates that 
“…it will be difficult to make a differ-
ence in the AIDS epidemic if HIV is
viewed in isolation from its root social,
economic, and political context; or if it
is seen only as a medical problem or as
an issue of individual behavior
change…”
In this scenario, the continent is gripped in a down-
ward spiral of disunity, denial and stigma, contested
knowledge, wasted resources, and competing sources
of power and authority. The capacity of systems,
people, and institutions to respond to the crises of AIDS
and underdevelopment are systematically diminished. 
The second scenario, entitled “Tough choices: Africa
takes a Stand”, describes what might transpire if
African countries, especially if collectively, mobilize and
nurture their own resources. In this setting, interna-
tional aid falters after an initial spurt of interest. This
scenario demonstrates that 
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“while there are enormous odds to
overcome, there is much that countries
in Africa can do with their own
strength to grow their economies, to
prioritize developmental objectives, to
lay the foundation for future growth
and development, and to reduce the
incidence and prevalence of AIDS.” 
In this scenario, effective African leadership at the
national and community levels make the choices
needed to accrue long-term benefits for their own
cultural, economic, and human potential. 
In the third scenario entitled “Times of Transition:
Africa Overcomes,” African governments stress “Pan-
African solidarity and high levels of regional co-opera-
tion…and put public good before private office,” much
as in the second scenario. In this last scenario, however,
the AIDS pandemic additionally acts as an international
catalyst fostering “a new global covenant, involving
security and human rights agendas brought together in
a coherent international framework that encompasses
economics, trade, social justice, and political reform.”
In such an environment, national autonomy is
promoted, African resources are consistently amplified
in ways that do not engender dependency, and marked
strides in health care development are possible.
CONCLUSION
As we move forward early in this twenty-first century
we must harness the lessons learned during the first 25
years of the human experience with HIV. This knowl-
edge must color the decisions made now if we are to
halt the complex forces driving the AIDS pandemic. The
outcome is not at all determined at the present time,
but the actions we take today will shape the evolution
of the AIDS pandemic far into the future. We are
provided choices at all levels. It is essential that we
embrace those with a lengthened perspective that will
ensure the development of effective policy and systems
with capacity and resources.   
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